<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Management of type 2 diabetes mellitus.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Management of type 2 diabetes mellitus. Ann Arbor (MI): University of Michigan Health System; 2012 Sep. 27 p.  [17 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Management of type 2 diabetes mellitus. Ann Arbor (MI): University of Michigan Health System; 2008 Jan. 21 p. [15 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The University of Michigan Health System released a minor revision in May 2014 to include information from the Eighth Joint National Committee (JNC8) and the American College of Cardiology/American Heart Association (ACC/AHA) that was released after the September 2012 publication of this guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication  (648.03); Diabetes with other coma, type II or unspecified type, not stated as uncontrolled  (250.30); Loss of weight  (783.21)"/><FieldValue Value="MSH: Adrenergic alpha-Antagonists ; Adrenergic beta-Antagonists ; Albuminuria ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Aspirin ; Blood Glucose ; Blood Glucose Self-Monitoring ; Blood Pressure Determination ; Calcium Channel Blockers ; Cardiovascular Diseases ; Counseling ; Diabetes Mellitus, Type 2 ; Diabetes, Gestational ; Diabetic Retinopathy ; Diagnostic Techniques, Neurological ; Diet Therapy ; Diuretics ; Drug Therapy ; Electrolytes ; Exercise ; Glomerular Filtration Rate ; Glucose Tolerance Test ; Goals ; Hemoglobin A, Glycosylated ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperlipidemias ; Hypertension ; Hypoglycemic Agents ; Insulin ; Life Style ; Metformin ; Peptides ; Podiatry ; Preconception Care ; Pregnancy in Diabetics ; Referral and Consultation ; Retinoscopy ; Risk Factors ; Self Care ; Smoking Cessation ; Sodium Chloride Symporter Inhibitors ; Sulfonylurea Compounds ; Thiazides ; Thiazoles ; Thiazolidinediones ; Venoms ; Weight Loss "/><FieldValue Value="MTH: Adrenergic alpha-Antagonists ; Adrenergic beta-Antagonists ; Albuminuria ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Aspirin ; Blood electrolyte measurement ; Blood Glucose ; Blood pressure determination ; Body Weight decreased ; Calcium Channel Blockers ; Cardiovascular Diseases ; Cessation of smoking ; Counseling ; Creatinine measurement, serum (procedure) ; Diabetes Mellitus screen ; Diabetes Mellitus, Non-Insulin-Dependent ; Diabetic Retinopathy ; Diet therapy ; Electrolytes ; Exercise ; Fasting blood glucose measurement ; Gestational Diabetes ; Glomerular Filtration Rate ; Glucohemoglobin measurement ; Glucose Tolerance Test ; Glycosylated hemoglobin A ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperlipidemia ; Hypertensive disease ; Insulin ; Life Style ; Microalbuminuria ; objective (goal) ; Pharmacotherapy ; Podiatry (discipline) ; Pregnancy in Diabetics ; Retinoscopy ; risk factors ; Self-care interventions ; Sodium Chloride Symporter Inhibitors ; Sulfonylurea Compounds ; Thiazide Diuretics ; Thiazides ; Thiazolidinediones ; Venoms "/><FieldValue Value="PDQ: acetylsalicyclic acid ; insulin "/><FieldValue Value="SNOMEDCT_US: Albumin measurement, urine, quantitative  (104486009); Albuminuria  (274769005); Alpha-adrenergic blocking agent  (373275009); Alpha-adrenergic blocking agent  (67440007); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Aspirin  (387458008); Aspirin  (7947003); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Blood electrolyte measurement  (312474003); Blood pressure taking  (46973005); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Counseling  (129441002); Counseling  (409063005); Creatinine measurement, serum  (113075003); Diabetes mellitus screening  (171183004); Diabetes self-management behavior  (405096004); Diabetes self-monitoring health education  (398773005); Diabetic retinopathy  (4855003); Disorder of cardiovascular system  (49601007); Diuretic  (30492008); Diuretic  (372695000); Drug therapy  (416608005); Electrolyte  (86355000); Examination of foot  (284384005); Examination of retina  (274798009); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fasting blood glucose measurement  (271062006); Gestational diabetes mellitus  (11687002); Glomerular filtration rate  (80274001); Glucohemoglobin measurement  (40402000); Glucose measurement, fasting  (52302001); Glucose tolerance test  (113076002); Glycosylated hemoglobin A  (33601001); Goal  (410518001); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hyperlipidemia  (55822004); Hypertensive disorder  (38341003); Hypoglycemic agent  (312064005); Hypoglycemic agent  (373299009); Insulin  (39487003); Insulin  (412222002); Insulin  (67866001); Life style  (134436002); Life style  (60134006); Metformin  (109081006); Metformin  (372567009); Microalbuminuria  (312975006); Monofilament foot sensation test  (134388005); Peptide  (52642002); Preconception care  (429070000); Retinoscopy  (397524001); Risk factor  (80943009); Self-care interventions  (384758001); Self-monitoring of blood glucose  (308113006); Sulfonylurea  (259552008); Sulfonylurea  (34012005); Sulfonylurea  (372711004); Thiazide diuretic  (372747003); Thiazide diuretic  (45518007); Thiazole  (428162000); Thiazolidinedione  (109086001); Thiazolidinedione  (372568004); Type 2 diabetes mellitus  (44054006); Venom  (37663002); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005)"/><FieldValue Value="UMD: Analyzers, Point-of-Care, Whole Blood, Glucose  (16-488)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;September 10, 2015 &amp;ndash; Invokana and Invokamet (canagliflozin)&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density. To address these safety concerns, FDA added a new WARNING AND PRECAUTION and revised the ADVERSE REACTIONS section of the Invokana and Invokamet drug labels. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm454141.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;July 9, 2015 - Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDS)&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. Based on FDA&amp;rsquo;s comprehensive review of new safety information, FDA is requiring updates to the drug labels of all prescription NSAIDs. As is the case with current prescription NSAID labels, the Drug Facts labels of over-the-counter (OTC) non-aspirin NSAIDs already contain information on heart attack and stroke risk. FDA will also request updates to the OTC non-aspirin NSAID Drug Facts labels. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Type 2 diabetes mellitus&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic complications&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults seen in primary care settings including those at risk for or diagnosed with diabetes mellitus&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Diet, exercise, and pharmacologic interventions&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screen for diabetes every 3 years or annually in certain circumstances &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;History for hypertension, gestational diabetes, or other risk factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine screening for cardiovascular risk factors (hypertension, hyperlipidemia, tobacco use) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diagnosis &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Fasting glucose test and confirmed by second test &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oral glucose tolerance test (OGTT) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Self-management education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle interventions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Goal setting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glycemic management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacologic management of hypertension and hyperlipidemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prompt treatment for cardiovascular risk factors (hypertension, hyperlipidemia, tobacco use) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Progression from impaired glucose tolerance (IGT) to diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Efficacy of treatments for diabetes and comorbidities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of treatments for diabetes and comorbidities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of co-morbid conditions, including hypertension, hyperlipidemia, smoking, use of aspirin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality rate among patient with diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychological status &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of end-stage outcomes of diabetes including blindness, renal failure, and amputation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cost of medical care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The literature search for this update began with the results of the literature searches performed in 1995 to develop the guideline and in 2003 for a major update that included literature through February 2003. The literature search conducted in April 2010 for this update used keywords that were similar to those used in previous searches, with the addition of a few new topics for searches. An exception was made for topics related to the diagnosis of diabetes mellitus. For these topics the recommendations of the American Diabetes Association's guidelines for Diagnosis and Classification of Diabetes Mellitus were accepted.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The searches for treatment were performed prospectively on Medline using the major key words of diabetes mellitus; clinical guidelines, controlled clinical trials, cohort studies; adults; and English language; and published from 1/1/2003 to present. Terms for specific topic searches within the major key words included: pre-diabetes or impaired fasting glucose tolerance; glycemic goal; lifestyle modifications: diet, exercise; treatment for type I diabetes: insulin; treatment for type II diabetes: sulfonylureas, metformin, alpha-glucosidase inhibitors, thiazolidinediones, nonsulfonyluric secretagogues (repaglinide, nateglinide), new insulins (glargine, aspart, lispro), exenatide, amylin, liraglutide; sitaglipitin, saxagliptin; screening and treatment for hypertension, lipids, retinopathy, nephropathy, neuropathy, macrovascular disease; and preconception planning in pregnancy. Specific search terms and strategy available upon request.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search was conducted in components each keyed to a specific causal link in a formal problem structure. The search was supplemented with very recent clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was single cycle.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Team members identified recent major evidence searches and major clinical trials. The evidence summary and clinical practice recommendations of the American Diabetes Association were the basis for screening and diagnosis recommendations. Glycemic control was based on the United Kingdom Prospective Diabetes Study (UKPDS) for control value and the American Diabetes Association (ADA) recommendations for goal. Life style modifications (diet, exercise) were based on the UKPDS and Diabetes Prevention Program (DPP) studies. The evidence summary and recommendations of the National Standards for Diabetes Self-Management Education were the basis for self-management recommendations. Comments about treatment for type 1 diabetes and insulin use are based on the Diabetes Control and Complications Trial (DCCT). Treatment for type 2 diabetes with sulfonylureas and metformin is based on the UKPDS. Screening and treatment of hypertension and lipid levels in type 2 diabetes is based on an evidence review and recommendations performed by the American College of Physicians, which included a member of our team. Screening and treatment for retinopathy were based on a literature review performed by the U.S. Veterans Administration. Recent evidence reviews were not available for the remaining topics.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Level of Evidence Supporting a Diagnostic Method or an Intervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conclusions were based on prospective randomized controlled trials if available, to the exclusion of other data. If randomized controlled trials were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size. The &quot;strength of recommendation&quot; for key aspects of care was determined by expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Generally should be performed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May be reasonable to perform &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generally should not be performed &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drafts of this guideline were reviewed in clinical conferences and by distribution for comment within departments and divisions of the University of Michigan Medical School to which the content is most relevant: Family Medicine; General Medicine; Geriatric Medicine; and Metabolism, Endocrinology, and Diabetes. The Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers endorsed the final version.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;em&gt;Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC)&lt;/em&gt;&lt;/strong&gt;: The following guidance was current as of September 2012. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/diabetes.html&quot; title=&quot;UMHS Web site&quot;&gt;original guideline document&lt;/a&gt; for the most current version.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The strength of recommendation (I-III) and levels of evidence (A-D) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following key points summarize the content of the guideline. Refer to the full text for additional information, including detailed information on dosing, possible side effects, and cost of medications for the management of type 2 diabetes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Key Points&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In individuals at risk for type 2 diabetes (see Table 1 in the original guideline document), type 2 diabetes can be delayed or prevented through diet, exercise, and pharmacologic interventions &lt;em&gt;[IA]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although little evidence is available on screening for diabetes, screening should be considered every 3 years beginning at age 45 or annually at any age if body mass index (BMI) &amp;ge;25 kg/m&lt;sup&gt;2&lt;/sup&gt; &lt;em&gt;[IID]&lt;/em&gt;, history of hypertension &lt;em&gt;[IIB]&lt;/em&gt;, gestational diabetes &lt;em&gt;[IC]&lt;/em&gt;, or other risk factors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A hemoglobin A1c (A1c) of 6.5% or greater, confirmed by a second test, is considered diagnostic of diabetes. Alternatively, diabetes can be diagnosed by two separate fasting glucoses &amp;ge;126 mg/dL; with symptoms, a glucose &amp;ge;200 mg/dL confirmed on a separate day by a fasting glucose &amp;ge;126 mg/dL; or 2-hour postload glucose &amp;ge;200 mg/dL during an oral glucose tolerance test &lt;em&gt;[B]&lt;/em&gt;. (See Table 1 in the original guideline document. See Table 2 in the original guideline document for differential diagnosis of diabetes.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Essential components of the treatment for diabetes include diabetes self-management education and support, lifestyle interventions, and goal setting (see Table 3 in the original guideline document); glycemic management (see Tables 4-10 in the original guideline document); and pharmacologic management of hypertension (see Table 11 in the original guideline document) and hyperlipidemia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Screening for Comorbidities and Complications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Routine screening and prompt treatment for cardiovascular risk factors (hypertension, hyperlipidemia, tobacco use) and for microvascular disease (retinopathy, nephropathy, neuropathy) are recommended in the time frames below.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment of Comorbidities and Complications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Management of risk factors and complications is summarized in Table 10 in the original guideline document. Diet, exercise, and pharmacologic interventions should be initiated for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hypertension &lt;em&gt;[IA]&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular risk reduction &lt;em&gt;[IA]&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperlipidemia &lt;em&gt;[IA]&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetes complications as indicated &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;br /&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Management of Type 2 Diabetes&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Each Regular Diabetes Visit&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Annually&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Blood pressure measured and controlled &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Check hemoglobin A1c every 3 months if on insulin; every 6 months if on oral agents or diet only and well-controlled &lt;em&gt;[II]&lt;/em&gt;. Optimize glycemic control &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Review and reinforce diet and physical activity &lt;em&gt;[IID]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Check weight, calculate body mass index (BMI) &lt;em&gt;[IID]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Feet should be inspected at each visit if neuropathy present. Otherwise visual foot exam and neuropathy evaluation annually &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Smoking cessation counseling provided for patients with tobacco dependence &lt;em&gt;[IB]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Review and reinforce key self-management goals (See Table 3 in the original guideline document) &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Dilated retinal examination by an eye care specialist: if good blood sugar and blood pressure control and previous eye exam was normal, every 2 years; if diabetic changes, annually or more frequently per eye care provider &lt;em&gt;[IB]&lt;/em&gt;. Treat retinopathy &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Screen for microalbuminuria if not already on an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) &lt;em&gt;[IB]&lt;/em&gt;. Prescribe an ACE inhibitor (or ARB, if ACE contraindicated) for microalbuminuria or proteinuria &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Screen for microalbuminuria if not on an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) &lt;em&gt;[IB]&lt;/em&gt;. Prescribe an ACE inhibitor or ARB for microalbuminuria or proteinuria &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Serum creatinine and estimated glomerular filtration rate (eGFR) &lt;em&gt;[ID]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Monofilament testing of feet (see Table 13 in the original guideline document) &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Prescribe moderate dose statin; measure lipids for adherence. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Smoking status assessed &lt;em&gt;[IB]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;All self-management goals reviewed and reinforced. (See Table 3 in the original guideline document). &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Influenza vaccination (annual) and confirm or give pneumococcal and hepatitis B vaccinations. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Special Considerations: Pregnancy&lt;/strong&gt;. Preconception counseling and glycemic control targeting a normal A1c in women with diabetes mellitus reduces the risk of congenital malformations and results in optimal maternal and fetal outcomes &lt;em&gt;[IB]&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Generally should be performed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May be reasonable to perform &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generally should not be performed &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Conclusions were based on prospective randomized controlled trials if available, to the exclusion of other data. If randomized controlled trials were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Improved adherence to important recommendations for preventing, detecting, and managing diabetic complications, which may lead to reduced morbidity and mortality&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Side Effects of Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Agents for Glycemic Management&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;For metformin, nausea and diarrhea are seen in up to 30% of patients; gastrointestinal side effects are dose related. Metformin extended release (XR) formulation may decrease diarrhea compared to the immediate release. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Compared to metformin, sulfonylureas have equivalent but less favorable effects on weight and increased risk of hypoglycemia. Additionally, weak evidence indicates that patients treated with sulfonylureas have higher cardiovascular mortality compared to patients treated with metformin. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gastrointestinal side effects of alpha-glucosidase inhibitors including abdominal pain, flatulence, and diarrhea are common. These effects usually diminish over time (4-8 weeks), but frequently lead to discontinuation of the drug. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Due to their side effect profile, thiazolidinediones (TZDs) should be considered third tier agents. TZDs are associated with significant weight gain. The U.S. Food and Drug Administration (FDA) has issued a box warning for both available TZDs due to an increased risk of congestive heart failure (CHF). Therefore these drugs should be avoided in patients with CHF. Both TZDs are associated with fluid retention and peripheral edema, which occur in at least 15% of patients. TZDs are strongly associated with increased fracture risk in post-menopausal women. TZDs may worsen diabetic macular edema. Renal dosage adjustment is not necessary. Pioglitazone has been associated with an increased risk of bladder cancer. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sodium-glucose cotransporter 2 (SGLT2) inhibitors work on the proximal renal tubules lowering the threshold for glucose excretion and increasing the urinary glucose clearance. This effect causes a light osmotic diuresis effect and net excretion of calories through the glucose urination. Hypoglycemia is rare when used as monotherapy. There are recommendations to dose reduce insulin or other concomitant insulin secretagogues. Although not indicated for hypertension or obesity, this class can cause hypotension and slight weight loss (~400 kcal/day, but only 2.5% weight loss in one trial at 52 weeks suggesting a compensatory mechanism). Dosage adjustments are required for renal insufficiency with both available agents and contraindicated below estimated glomerular filtration rate (eGFR) of 30 ml/min. Hepatic dosage adjustment is only required for canagliflozin in Child-Pugh class C. Studies show an increased risk for urinary tract infections as well as genital mycosis infections in users as the most common side effects. There was an increase of bladder cancer among users of dapagliflozin in clinical trials suggesting avoiding use in patients with a history of bladder cancer. Long term renal safety data is currently unavailable. Trials have shown a slight increase in serum creatinine, decreases in eGFR and elevations in low density lipoprotein cholesterol (LDL-C). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The most common side effects of incretin mimetic agents are nausea and vomiting. The FDA warns that exenatide may be associated with an increased risk for pancreatitis and subsequent acute renal failure. If pancreatitis is suspected, incretin mimetic agents should be discontinued. If pancreatitis is confirmed, exenatide should not be restarted unless an alternative etiology for the pancreatitis is identified. Exenatide should be used cautiously in those with glomerular filtration rate (GFR) between 30 and 50, with careful monitoring of renal function and gastrointestinal side effects. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symlin is used at mealtimes to augment the effects of insulin on glycemic control. This can cause hypoglycemia which can occur within 3 hours after a symlin injection. Symlin and insulin should never be mixed in the same syringe. Symlin can also suppress appetite and lead to weight loss. Nausea is the most common side effect but improves with time in most patients. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;See also, Table 7 in the original guideline document for a summary of side effects and precautions for agents for glycemic control.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Antihypertensive Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The combination of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) should be avoided. Although together they reduce blood pressure and proteinuria, they also clearly increase the rate of end-stage renal disease mortality. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High-dose thiazide diuretics have been reported to have a variety of adverse effects including worsening of hyperlipidemia, hyperuricemia and gout flares, deterioration of glycemic control, impotence, and increased mortality, therefore thiazides should be used at low doses. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Beta-blockers may decrease high density lipoprotein (HDL) and increase triglyceride levels. In one major trial beta-blockers led to more weight gain and higher requirements for glucose-lowering agents than angiotensin-converting enzyme (ACE) inhibitors. If a beta-blocker is used, it should be cardioselective to minimize side-effects. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACE inhibitors can lead to cough in up to 20% of patients. Both ACE inhibitors and ARBs can lead to renal insufficiency and hyperkalemia. Therefore careful monitoring of renal function and serum electrolytes is therefore warranted with these agents. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Lipid Lowering Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Avoid prescribing simvastatin 80 mg because of the increased risk of myalgias. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful monitoring of potential drug interactions with statins is critical; many drugs can increase the risk of myalgias and rhabdomyolysis when combined with statins. See the National Guideline Clearinghouse (NGC) summary of the University of Michigan Health System (UMHS) guideline &lt;a href=&quot;/content.aspx?id=48194&quot; title=&quot;Guideline #10399&quot;&gt;Screening and Management of Lipids&lt;/a&gt; for information regarding drug interactions with statins. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Agents for Treatment of Diabetic Peripheral Neuropathy (PDN)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Non-steroidal anti-inflammatory drugs (NSAIDS) should be used cautiously for chronic neuropathic pain due to their gastrointestinal and renal side effects that are of concern in this population. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tricyclic antidepressants (TCAs) may be used to treat painful neuropathy and their use is supported by research. They should be used with caution in the elderly, started at low doses and titrated to maximize pain relief while minimizing side effects of dry mouth, sedation, orthostatic hypotension, and constipation. Nortriptyline is the preferred tricyclic as it has fewer anticholinergic properties. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sedation is a side effect of gabapentin that limits its use. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of carbamazepine and valproate is limited by their side effect profiles. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As a last option, opioids may be considered, though general use is discouraged. See the NGC summary of the UMHS guideline &lt;a href=&quot;/content.aspx?id=25657&quot; title=&quot;Guideline #8275&quot;&gt;Managing Chronic Non-Terminal Pain in Adults Including Prescribing Controlled Substances&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Other Potential Harms&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Risk of tight control&lt;/em&gt;: The major risk of intensive glycemic control is hypoglycemia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Factors heightening risk of tight glycemic control&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;History of severe hypoglycemia (inability to treat without assistance) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypoglycemia unawareness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Advanced cardiovascular or cerebrovascular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Autonomic neuropathy (especially cardiac) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Comorbidities that impair the detection of hypoglycemia (e.g., alteration in mental status, alcoholism, etc.). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Poor social support &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Metformin should be avoided in patients with reduced creatinine clearance or who are at risk for the rare complication of lactic acidosis (e.g., patients with cirrhosis or severe congestive heart failure [CHF]). It should be withheld in clinical settings such as intravenous contrast administration, surgery, or dehydration. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exenatide should not be used in those with glomerular filtration rate (GFR) &amp;lt;30. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The U.S. Food and Drug Administration has issued a black box warning for both available thiazolidinediones due to an increased risk of CHF; therefore these drugs should be avoided in patients with significant CHF. Thiazolidinediones (TZDs) are associated with fluid retention and peripheral edema, which occur in at least 15% of patients. TZDs are strongly associated with increased fracture risk in post-menopausal women. TZDs may worsen diabetic macular edema. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Some members of the dihydropyridine class of calcium channel blockers (e.g., nifedipine, felodipine) may increase urinary albumin excretion, and should be avoided in patients with microalbuminuria. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For patients with any renal impairment, glipizide is preferred. Severe hypoglycemia can occur in patients with significant renal impairment. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;See also, Table 7 in the original guideline document for a summary of contraindications to agents for glycemic control.&lt;/p&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Patient Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Management of type 2 diabetes mellitus. Ann Arbor (MI): University of Michigan Health System; 2012 Sep. 27 p.  [17 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1996 May (revised 2012 Sep)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="University of Michigan Health System - Academic Institution" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Diabetes Mellitus Guideline Team&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Team Leaders&lt;/em&gt;: Connie J Standiford, MD, General Internal Medicine; Sandeep Vijan, MD, General Internal Medicine&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Team Members&lt;/em&gt;: Hae Mi Choe, PharmD, College of Pharmacy; R Van Harrison, PhD, Medical Education; Caroline R Richardson, MD, Family Medicine; Jennifer A Wyckoff, MD, Metabolism, Endocrinology &amp;amp; Diabetes&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Consultants&lt;/em&gt;: Martha M Funnell, MS, RN, CDE, Diabetes Research and Training Center; William H Herman, MD, Metabolism, Endocrine &amp;amp; Diabetes&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Disclosure of Relationships&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Team Member/&lt;br /&gt;&#xD;&#xA;            Consultant&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Company&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Relationship&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Hae Mi Choe, PharmD&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Martha M. Funnell, MS, RN, CDE&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Boehringer Ingelheim, Bristol-Myers Squibb/AstraZeneca, Halozyme Thera-peutics, Eli Lilly, Animas/Lifescan, Hygieia Inc, Intuity Medical&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Advisory Boards&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;R. Van Harrison, PhD&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;William H. Herman, MD, MPH&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cebix, Genentech, McKinsey &amp;amp; Co., Sanofi-Aventis, VeraLight&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consultant&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Caroline R. Richardson, MD&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Connie J. Standiford, MD&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Sandeep Vijan, MD&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Jennifer A. Wycoff, MD&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Management of type 2 diabetes mellitus. Ann Arbor (MI): University of Michigan Health System; 2008 Jan. 21 p. [15 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The University of Michigan Health System released a minor revision in May 2014 to include information from the Eighth Joint National Committee (JNC8) and the American College of Cardiology/American Heart Association (ACC/AHA) that was released after the September 2012 publication of this guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/diabetes.html&quot; title=&quot;University of Michigan Health System Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Continuing Medical Education (CME) information is available from the &lt;a href=&quot;http://ocpd.med.umich.edu/cme/self-study/Diabetes:%20Management%20of%20Type%202%20Diabetes&quot; title=&quot;University of Michigan Health System Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Several patient education resources about diabetes are available from the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/diabetes.html&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on May 20, 1999. The information was verified by the guideline developer on June 17, 1999. This NGC summary was updated by ECRI on October 12, 2004. The updated information was verified by the guideline developer on October 22, 2004. This summary was updated on May 3, 2005 following the withdrawal of Bextra (valdecoxib) from the market and the release of heightened warnings for Celebrex (celecoxib) and other nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). This summary was updated by ECRI on June 16, 2005, following the U.S. Food and Drug Administration advisory on COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). This summary was updated by ECRI on January 11, 2006 following the U.S. Food and Drug Administration advisory on rosiglitazone. This summary was updated by ECRI Institute on September 5, 2007 following the U.S. Food and Drug Administration advisory on the Thiazolidinedione class of antidiabetic drugs. This summary was updated by ECRI Institute on November 6, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs. This NGC summary was updated by ECRI Institute on January 23, 2008. The information was verified by the guideline developer on February 11, 2008. This summary was updated by ECRI Institute on March 10, 2008 following the U.S. Food and Drug Administration advisory on Avandia (rosiglitazone maleate). This summary was updated by ECRI Institute on May 1, 2009 following the U.S. Food and Drug Administration advisory on antiepileptic drugs. This summary was updated by ECRI Institute on November 18, 2009 following the U.S. Food and Drug Administration advisory on Byetta (exenatide). This summary was updated by ECRI Institute on November 8, 2010 following the U.S. Food and Drug Administration advisory on Avandia (rosiglitazone). This summary was updated by ECRI Institute on June 27, 2011 following the U.S. Food and Drug Administration advisory on Zocor (simvastatin). This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs. This NGC summary was updated by ECRI Institute on December 12, 2012. This summary was updated by ECRI Institute on September 17, 2015 following the U.S. Food and Drug Administration advisory on Invokana and Invokamet (canagliflozin). This summary was updated by ECRI Institute on September 18, 2015 following the U.S. Food and Drug Administration advisory on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
